new BindingDB logo
myBDB logout

BDBM50403867 CHEMBL2115098

SMILES: OC(=O)C[C@H](NC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)c1ccc2OCOc2c1

InChI Key: InChIKey=OXVBGNHXQPUFKF-HNNXBMFYSA-N

Data: 3 IC50

Find this compound or compounds like it in BindingDB or PDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 50403867   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kcal/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
ITGAV/ITGB3


(Homo sapiens (Human))
BDBM50403867
PNG
(CHEMBL2115098)
Show SMILES OC(=O)C[C@H](NC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)c1ccc2OCOc2c1 |r,t:17|
Show InChI InChI=1S/C22H24N4O6S/c27-19(26-22-23-8-1-9-24-22)7-4-14-3-6-18(33-14)21(30)25-15(11-20(28)29)13-2-5-16-17(10-13)32-12-31-16/h2-3,5-6,10,15H,1,4,7-9,11-12H2,(H,25,30)(H,28,29)(H2,23,24,26,27)/t15-/m0/s1
PDB

UniProtKB/SwissProt

antibodypedia
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
PubMed
n/an/a 9n/an/an/an/an/an/a



Aventis Pharma Deutschland GmbH

Curated by ChEMBL


Assay Description
Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%


Bioorg Med Chem Lett 11: 2011-5 (2001)


BindingDB Entry DOI: 10.7270/Q2N87930
More data for this
Ligand-Target Pair
Integrin alpha-IIb/beta-3


(Homo sapiens (Human))
BDBM50403867
PNG
(CHEMBL2115098)
Show SMILES OC(=O)C[C@H](NC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)c1ccc2OCOc2c1 |r,t:17|
Show InChI InChI=1S/C22H24N4O6S/c27-19(26-22-23-8-1-9-24-22)7-4-14-3-6-18(33-14)21(30)25-15(11-20(28)29)13-2-5-16-17(10-13)32-12-31-16/h2-3,5-6,10,15H,1,4,7-9,11-12H2,(H,25,30)(H,28,29)(H2,23,24,26,27)/t15-/m0/s1
PDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
PubMed
n/an/a>1.00E+4n/an/an/an/an/an/a



Aventis Pharma Deutschland GmbH

Curated by ChEMBL


Assay Description
Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%


Bioorg Med Chem Lett 11: 2011-5 (2001)


BindingDB Entry DOI: 10.7270/Q2N87930
More data for this
Ligand-Target Pair
ITGAV/ITGB3


(Homo sapiens (Human))
BDBM50403867
PNG
(CHEMBL2115098)
Show SMILES OC(=O)C[C@H](NC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)c1ccc2OCOc2c1 |r,t:17|
Show InChI InChI=1S/C22H24N4O6S/c27-19(26-22-23-8-1-9-24-22)7-4-14-3-6-18(33-14)21(30)25-15(11-20(28)29)13-2-5-16-17(10-13)32-12-31-16/h2-3,5-6,10,15H,1,4,7-9,11-12H2,(H,25,30)(H,28,29)(H2,23,24,26,27)/t15-/m0/s1
PDB

UniProtKB/SwissProt

antibodypedia
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
PubMed
n/an/a 1.43E+3n/an/an/an/an/an/a



Aventis Pharma Deutschland GmbH

Curated by ChEMBL


Assay Description
Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%


Bioorg Med Chem Lett 11: 2011-5 (2001)


BindingDB Entry DOI: 10.7270/Q2N87930
More data for this
Ligand-Target Pair